Do you want to read an article? Please log in or register.
Fatty Acid-Binding Protein 4 and Risk of Type 2 Diabetes, Myocardial Infarction and Stroke: A Prospective Cohort Study
Type 2 Diabetes
Related content
COMMENTED
Type 2 Diabetes
Insulin-Like Growth Factor Binding Protein 2 (IGFBP-2) and the Risk of Developing Type 2 Diabetes
Diabetes.
Wittenbecher C, Ouni M, Kuxhaus O, Jähnert M, Gottmann P, Teichmann A, Meidtner K, Kriebel J, Grallert H, Pischon T, Boeing H, Schulze MB, Schürmann A
doi: 10.2337/db18-0620.
COMMENTED
Type 2 Diabetes
Associations of circulating very-long-chain saturated fatty acids and incident type 2 diabetes: a pooled analysis of prospective cohort studies
doi: 10.1093/ajcn/nqz005.
Type 2 Diabetes
Plasma fatty acids and the risk of vascular disease and mortality outcomes in individuals with type 2 diabetes: results from the ADVANCE study
Diabetologia.
Harris K, Oshima M, Sattar N, Würtz P, Jun M, Welsh P, Hamet P, Harrap S, Poulter N, Chalmers J, Woodward M
doi: 10.1007/s00125-020-05162-z.
COMMENTED
Glycemic Control
Glycemic Control and Risk of Infections Among People With Type 1 or Type 2 Diabetes in a Large Primary Care Cohort Study
Diabetes Care.
Critchley JA, Carey IM, Harris T, DeWilde S, Hosking FJ, Cook DG
doi: 10.2337/dc18-0287.
Diabetes - GeneralType 2 DiabetesObesity and Bariatric Surgery
Age at natural menopause and risk of type 2 diabetes: a prospective cohort study
Diabetologia.
Muka T, Asllanaj E, Avazverdi N, Jaspers L, Stringa N, Milic J, Ligthart S, Ikram MA, Laven JSE, Kavousi M, Dehghan A, Franco OH
doi: 10.1007/
Diabetes - GeneralType 2 DiabetesObesity and Bariatric Surgery
Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study
Diabetologia.
Eriksson JW, Lundkvist P, Jansson PA, Johansson L, Kvarnström M, Moris L, Miliotis T, Forsberg GB, Risérus U, Lind L, Oscarsson J
doi: 10.1007/s00125-018-4675-2.
COMMENTED
Type 2 Diabetes
Dietary Intake of Linoleic Acid, Its Concentrations, and the Risk of Type 2 Diabetes: A Systematic Review and Dose-Response Meta-analysis of Prospective Cohort Studies
★ 1
Recommended and commented by
Prof. emer. Dr Ulrich Keller, Faculty Member
Diabetes Care
Mousavi SM, Jalilpiran Y, Karimi E, Aune D, Larijani B, Mozaffarian D, Willett WC, Esmaillzadeh A
doi: 10.2337/dc21-0438
COMMENTED
Diabetes - GeneralType 2 Diabetes
Sulfonylureas as second line drugs in type 2 diabetes and the risk of cardiovascular and hypoglycaemic events: population based cohort study
BMJ
Douros A, Dell'Aniello S, Yu OHY, Filion KB, Azoulay L, Suissa S
doi: 10.1136/bmj.k2693.
COMMENTED
Type 2 Diabetes
Risk of cardiovascular events and death associated with initiation of SGLT2 inhibitors compared with DPP-4 inhibitors: an analysis from the CVD-REAL 2 multinational cohort study
★ 2
Recommended and commented by
Prof. emer. Dr Ulrich Keller, Faculty Member
Lancet Diabetes Endocrinol.
Kohsaka S, Lam CSP, Kim DJ, Cavender MA, Norhammar A, Jørgensen ME, Birkeland KI, Holl RW, Franch-Nadal J, Tangri N, Shaw JE, Ilomäki J, Karasik A, Goh SY, Chiang CE, Thuresson M, Chen H, Wittbrodt E, Bodegård J, Surmont F, Fenici P, Kosiborod M, CVD-REAL 2 Investigators and Study Group
doi: 10.1016/S2213-8587(20)30130-3.